Board of Directors
President and CEO
Douglas Doerfler has over 30 years experience in the discovery, development and international financing and
commercialization of biotechnology products and companies. He joined MaxCyte as its founding President and
CEO in June 1999.
Prior to joining MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a
privately owned biotechnology holding company. He was President, Chief Executive Officer and a Director of Immunicon
Corporation, a cell-based therapy and diagnostics company. Doug also held various executive positions with Life
Technologies that included leading global businesses, mergers and acquisitions and its IPO.
Doug plays an active role as an advocate for the life sciences industry and serves on the Biotechnology Industry
Organization's Board of Directors and Co-Chairs BIO's Capital Formation Committee. He is Chairman of the Tech Council
of Maryland and serves on the Executive Committee of the Alliance for Regenerative Medicine.
Doug received his B.S. in Finance from the University of Baltimore School of Business and holds a certificate in
Karen A. Donato, Ph.D.
Executive Vice President, Global Business Development & Marketing
Karen A. Donato, Ph.D., joined MaxCyte in 2008 and currently serves as Executive Vice President of Global Business
Development & Marketing. Dr. Donato has over fifteen years of experience in sales and marketing of products and
services in life sciences, coupled with product and process development experience in biomedical materials and
polymers. Prior to joining MaxCyte, Dr. Donato headed up business development for Summit Drug Development
Services, a regulatory consulting firm. Earlier, Dr. Donato led an international sales and marketing team at
Celsis|In Vitro Technologies, focused on drug discovery tools for ADME-Tox applications. From 1995-2006, Dr.
Donato held positions of increasing levels of responsibility in sales and marketing at TherImmune Research
Corporation, which was acquired by Gene Logic during her tenure. At TherImmune and Gene Logic Labs, Dr. Donato
was instrumental in the establishment of strategic business relationships with major pharmaceutical and
biotechnology companies. Dr. Donato has been involved in R&D and manufacturing in engineering positions at
Hoechst Celanese, Ethicon (a Johnson & Johnson Company), and DuPont.
Dr. Donato earned a B.S.E. from the University of Pennsylvania and an M.S. and a Ph.D. from Ohio University, all in
Chemical Engineering. Dr. Donato also holds three issued patents in drug delivery.
Chief Financial Officer
Ronald Holtz serves as MaxCyte's Chief Financial Officer. During his career, Mr. Holtz has been CFO of both public and
private companies and has raised more than $100m in debt and equity capital. Prior to joining MaxCyte, Mr. Holtz was
Chief Financial Officer of B2eMarkets, Inc. a privately held software solutions company targeting Global 1000 companies.
Mr. Holtz also served as Vice President and Chief Financial Officer of RWD Technologies, Inc., a leading information
technology and performance improvement consulting firm. As CFO, Holtz led RWD's highly successful initial public offering
and was responsible for finance, acquisitions, business management and analyst/investor relations. Previously, Mr. Holtz
was a manager in Ernst & Young LLP's Financial Advisory Services Group. Mr. Holtz is also a founding member of the Robert H.
Smith School of Business Finance Advisory Board at the University of Maryland. He earned a Master's of Business Administration
in finance from the University of Maryland, a bachelor's of science degree in mathematics from the University of Wisconsin
and is a CPA.
Madhusudan Peshwa, Ph.D.
Vice President, Global Sales
Executive Vice President, Cellular Therapies
Madhusudan Peshwa, Ph.D., currently serves as Vice President, Research and Development at MaxCyte, Inc. Most recently,
he was Executive Vice President for Research and Development at NewNeural LLC, a start-up stem cell therapy company.
Earlier he served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation
(NASDAQ: DNDN), where we was responsible for development, characterization and manufacture of an autologous dendritic
cell vaccine product from concept to late Phase III pivotal studies. His expertise is in the areas of design,
characterization, scale-up and implementation of processes, and cGMP systems in the development of engineered cell and
tissue products and for biopharmaceuticals' production.
Dr. Peshwa obtained his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical
Engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications
and is a co-inventor on five, issued or under review, patent applications.
Mark Schmeizl serves as MaxCyte's Vice President of Global Sales. Mr. Schmeizl brings over 20 years sales and marketing
experience in drug discovery, genomics, and life science research tools. He has repeatedly built and led highly successful
commercial teams for leading life science companies including Aushon BioSystems, Cisbio, Affymetrix, and Perkin Elmer
(formerly Packard BioSciences). Most recently, he served as a sales management consultant for Forge 4ward where he helped
early phase life science companies map out market penetration strategies and build sales teams. Mr. Schmeizl earned his BS
in biology at the University of Connecticut.
Board of Directors
J. Stark Thompson, Ph.D.
Chairman of the Board
Dr. Thompson is the former President and CEO of Life Technologies Inc. (now Invitrogen). Dr. Thompson has over thirty
years of experience in life sciences technology development and commercialization. From 1988 to 2000, Dr. Thompson
served as President and Chief Executive Officer of Life Technologies Inc. and was on the Executive Committee of its
largest shareholder Dexter Corporation. Prior to joining Life Technologies, Dr. Thompson served in multiple positions
of increasing responsibility over a period of 21 years at DuPont de Nemours and Co., a diversified chemical company.
Dr. Thompson held numerous positions at DuPont de Nemours and Co. such as Business Director of the Clinical Systems
Division, Manager of the Instruments Systems Division and Manager of Health Care Business Planning. Dr. Thompson
received his B.S. in Chemistry from Muskingum College and Ph.D. in Physiological Chemistry from Ohio State University.
Dr. Thompson is currently a member of the executive committees of several educational and non-profit organizations and
serves as a member of the Board of Directors of Luminex (Nasdaq:LMNX) and Chairman of the Board of GeneLogic (Nasdaq:GLGC)
William W. Brooke is Managing Partner of Harbert Venture Partners and oversees Harbert's Life Science investments. He
also is a Partner of the Harbinger/Aurora Venture Funds, and has served on their Investment Committee and Members'
Advisory Committee. Mr. Brooke has been advising start-up companies for more than twenty years, and currently serves
on the boards of AV Holdings (Atherotech), Emageon and MaxCyte. As EVP and board member of Harbert for over ten years,
Mr. Brooke initially served as the firm's General Counsel and later as its Chief Operating Officer. Mr. Brooke is a guest
lecturer on venture capital at the MBA programs at the University of Alabama and the University of Alabama in Birmingham.
Mr. Brooke holds degrees in Law and Business Management from the University of Alabama.
Douglas A. Doerfler
President and CEO
Douglas Doerfler has over 25 years experience in the discovery, development and international financing and commercialization
of biotechnology products and companies. He joined MaxCyte as its founding President and CEO in June 1999. Prior to joining
MaxCyte, he held senior corporate development and operating responsibilities for PFRM, Inc., a privately owned biotechnology
holding company. He was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and
diagnostics company. Mr. Doerfler also held various executive positions with Life Technologies that included leading global
businesses, mergers and acquisitions and public offerings. Mr. Doerfler plays an active role as an advocate for the life
sciences industry and serves on the Biotechnology Industry Organization's Board of Directors Executive Committee, and
Co-Chairs BIO's Capital Formation Committee. He is a member of the Executive Committees of the Maryland High Technology
Council and the Alliance for Regenerative Medicine. He is also Chairman of MDBio. Doug received his B.S. in Finance from
the University of Baltimore School of Business and a certificate in Industrial Relations.
Mr. Erck, President and CEO, and Director of Novavax Corporation, applies his 25 years of management experience in the healthcare and biotechnology industry (Baxter International, Procept, Integrated Genetics, and Iomai) to shepherd the development and commercialization of Novavax technology. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, as CEO he has managed the process of developing companies from private funding through IPO. Mr. Erck received his B.S. from the University of Illinois and an M.B.A. from the University of Chicago.
Chris Hegele joined Intersouth Partners in 2003. He is a long standing member of the Southeast's venture capital community,
having spent nearly 20 years as a general partner with Kitty Hawk Capital, a venture capital firm located in Charlotte,
North Carolina. Kitty Hawk was founded in 1980 and manages $100 million in four venture capital funds. Prior to joining
Kitty Hawk in 1984, Chris was with Arthur Andersen & Co. in its Small Business Group.
Arthur M. Mandell
A. Sinclair Dunlop
Mr. Mandell is a senior executive in the health care industry with over 30 years of experience running companies, executing large corporate and business development deals in both the pharmaceutical and biotechnology sectors, and developing and commercializing a number of products. Mr. Mandell served as President and Chief Operating Officer of Prestwick Pharmaceuticals, Inc. in Washington, DC. – a healthcare company focused on late stage Central Nervous System drugs. Prior to Prestwick, Mr. Mandell was President, Chief Executive Officer, and a Director of Cellective Therapeutics, Inc., a Maryland-based monoclonal antibody company developing therapeutic products for autoimmune and oncology diseases. Under his leadership, Cellective was acquired by one of the largest biotechnology firms in the world, MedImmune Inc. Before Cellective, Mr. Mandell served as President, Chief Executive Officer, and Director of Stemron Corporation, a therapeutic stem cell start up company in Gaithersburg, Maryland and prior to joining Stemron Corporation; he served as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. (HGS), an iconic biotechnology leader in Gaithersburg, Maryland. Mr. Mandell began his career in California, where he spent over 13 years in various leadership positions, both domestic and international, at Syntex Corporation in Palo Alto, California. Just prior to its acquisition by F. Hoffman-La Roche, he was responsible for the Pacific Sector including all operations in Asia, South America, Mexico and Canada. Mr. Mandell also has experience in the service sector as Partner and West Coast General Manager for ZS Associates, a successful healthcare consulting firm headquartered in Evanston, Illinois. He established ZS' 3rd office. They currently have over 50 offices worldwide. Mr. Mandell currently serves as a Director for Maxcyte Corporation, Executive Chairman for Hook and Ladder Brewing Company and is on the Advisory Boards of Mt. Weather Capital and LiveChime, Inc.
Mr. Dunlop has almost two decades of international experience in evaluating early-stage biotechnology companies. As the Founder and Managing Partner of MASA Life Science Ventures he leads the review and analysis of Fund investment candidates. A former international business and economics analyst with the Center for Strategic & International Studies in Washington, D.C., Mr. Dunlop has private equity and venture capital experience in East Asia, Europe, the U.S. and Israel. Mr. Dunlop received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also holds an M.A. with Honors in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. Mr. Dunlop currently serves on the Boards of Engene Inc., Mediquest Therapeutics Inc., MaxCyte Inc. and Potentia Pharmaceuticals Inc.
Michael R. Blaese, M.D.
Formerly National Institutes of Health
Dr. Blaese was on the faculty of the National Institutes of Health for 33 years where his work spanned a range of areas from basic research in immunology, virology, cancer and molecular genetics to clinical investigation and the development of innovative new therapies. In 1984 he started work to develop the use of genes as medicines that ultimately led to the first successful human gene therapy in 1990. As Chief of Clinical Gene Therapy for the Human Genome Institute, Mike continued to lead the early development of gene therapy introducing clinical trials for inherited immunodeficiency, brain cancer and AIDS. He has served widely on Biotech SABs and government advisory committees and in 1999 he joined Kimeragen (later ValiGen) as Chief Scientific Officer and President of their Molecular Pharmaceuticals Division. He has published over 340 original research papers, holds 11 patents and was instrumental in policy formation governing gene technology in the U.S. at the NIH, FDA and the RAC (Recombinant DNA Advisory Committee) as well as consulting on these topics for the Parliaments of France and Denmark. Most recently Dr. Blaese serves as Research Director of the Fund for Inherited Disease Research, Founder and President of PreGentis and as Medical Director of the Immune Deficiency Foundation.
Robert Gerety, M.D., Ph.D.
MEND (Medicine in Need)
With 15 years of experience at the Food and Drug Administration (FDA) and the National Institutes of Health and 14 years as an executive in the pharmaceutical and biotechnology industries, Dr. Gerety brings a wealth of experience to his position as Vice President and Principal Fellow with Nektar. While with the FDA, Dr. Gerety served as associate director for medicine and science and chief of the infectious disease branch at the Office for Biologics Evaluation and Research. Dr. Gerety also has held executive positions in regulatory affairs and research and development at several pharmaceutical companies. Prior to joining Inhale Therapeutics Systems, Dr. Gerety was vice president of development and regulatory affairs at OraVax, Inc. a biotechnology company engaged in the discovery and development of vaccines and antibody products. At Merck & Co., he directed the licensing of the first recombinant human vaccine against hepatitis B and establishing Shionogi as the Japanese commercialization partner. As vice president of development operations at Biogen, Inc., he was instrumental in championing the development of AVONEX¨ (interferon beta-1a), the leading drug used in the treatment of multiple sclerosis. Dr. Gerety was executive vice president and later CEO of ImmuLogic Pharmaceutical Corporation. Dr. Gerety has been a member of the United States Public Health Service, the National Vaccine Advisory Committee of the U.S. government, US Japan Scientific collaboration of Hepatitis, and the AIDS Task Force and has served as a consultant to the NIAID, the NCI, the U.S. Army, the American Red Cross, and the World Health Organization. He received his MA and PhD from Stanford University Medical School and his MD from the George Washington University School of Medicine.
James Weaver, Ph.D.
John Reardon, Ph.D.
Integrated Oncology Solutions, Inc.
Massachusetts Institute of Technology
James C. Weaver, Ph.D., is a Senior Research Scientist in the Harvard-MIT Division of Health Sciences and Technology on the MIT campus. Dr. Weaver has published more than one hundred peer-reviewed scientific papers, has twenty-four issued patents, and in 2000 was elected Fellow of the American Institute for Medical and Biological Engineering. His research has emphasized electromagnetic field effects in cells and tissues, with a focus on the fundamental mechanism of cell electroporation and its biomedical applications. Dr. Weaver received his BA from Carleton College, and MS and PhD degrees in Physics from Yale University.
John E Reardon is the Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions, Inc., a biopharmaceutical company headquartered in Research Triangle Park, NC. Prior to joining IOS Dr. Reardon was the Senior Vice President of Discovery Research Biology at GlaxoSmithKline with responsibility for the majority of biological science supporting gene-to-function-to-target-to-lead activities in the international GSK R&D organization. Dr. Reardon received his Ph.D. degree in Chemistry from The Ohio State University and did post-doctoral research with Dr. Robert Abeles at Brandeis University before beginning a career in the pharmaceutical industry. He joined Burroughs Wellcome Co. in 1987 as a Research Scientist where he contributed to the discovery and development of several anti-viral compounds.